ARCHIVES

Cancer Organizations Continue Reform Lobbying: Target Issue Are Off-Label Drugs, Clinical Trials

This article is from The Cancer Letter archive.

Vol. 19 No. 13 | March 26, 1993

Download PDF Visit The Full Archive

Related Articles

HAI Delivery Extends Survival In Patients With Liver Metastasis

March 31, 2006

Broder Encourages Support Of Drug Development Programs

March 10, 1995

Broder Appointment Official; Will Keep Retroviral Laboratory, Will Not Serve as NCI Clinical Director

January 6, 1989

ONS Membership Still Climbing, Soars over 15,000

June 23, 1989

Clinical Trials: “Master Protocol” To Rely On Biomarkers In Testing Multiple Lung Cancer Agents

November 15, 2013

FDA Approves Afinitor For Advanced Kidney Cancer

March 27, 2009